Results 41 to 50 of about 41,581 (185)

Optimization of pharmaceutical research and development by early‐phase assessment of investigational medicinal products

British Journal of Clinical Pharmacology, EarlyView.
Small and mid‐sized pharmaceutical innovators often have limited in‐house health economics and market access expertise, and may struggle to align development strategies of investigational medicinal products with health system needs and payer expectations.
Zoltán Kaló, Attila Imre, Gábor Varga, Sándor Kovács, György Tímár, Balázs Nagy   +5 more
wiley   +1 more source

Effect of polymorphisms in drug metabolism and transportation on plasma concentration of atorvastatin and its metabolites in patients with chronic kidney disease

Frontiers in Pharmacology, 2023
Dyslipidemia due to renal insufficiency is a common complication in patients with chronic kidney diseases (CKD), and a major risk factor for the development of cardiovascular events.
Zebin Jiang, Zemin Wu, Ruixue Liu, Qin Du, Xian Fu, Min Li, Yongjun Kuang, Shen Lin, Jiaxuan Wu, Weiji Xie, Ganggang Shi, Yanqiang Peng, Fuchun Zheng, Fuchun Zheng   +13 more
doaj   +1 more source

Risk of venous thromboembolism after SARS‐CoV‐2 vaccination—Evidence from genome‐wide association study and population‐based observational study

British Journal of Clinical Pharmacology, EarlyView.
Aim We aimed to investigate whether genetic variation is associated with venous thromboembolism after immunization with SARS‐CoV‐2 vaccines. Methods We conducted a genome‐wide association study (GWAS) on cases of venous thromboembolism within 42 days after SARS‐CoV‐2 vaccination, recruited from reports of adverse drug reactions sent to the Swedish ...
Sofia Attelind, Niclas Eriksson, Marco Cavalli, Yiyi Xu, Fredrik Nyberg, Anders Sundström, Mia Wadelius, Pär Hallberg   +7 more
wiley   +1 more source

Efficacy of combined atorvastatin and argatroban therapy in acute cerebral infarction

Pakistan Journal of Pharmaceutical Sciences
Background: Acute cerebral infarction (ACI) is a disease which seriously affects the people's health. Objectives: To investigate the efficacy of combined atorvastatin and argatroban therapy in patients with ACI and its effects on cerebral hemodynamics ...
Weihua Xu, Ni Zhai, Yanan Wang, Jie Chen, Zhiwei Li, Licang Zhu   +5 more
doaj   +1 more source

Prediction and validation of common targets in atherosclerosis and non-small cell lung cancer influenced by atorvastatin

BMC Complementary Medicine and Therapies, 2023
Background Cardiovascular disease and cancer are the main causes of morbidity and mortality worldwide. Studies have shown that these two diseases may have some common risk factors.
Yu-qian Li, Lu-yao Li, Xue Yang, Qi-qi Lei, Liu-yan Xiang, Yuan-ru Wang, Si-meng Gu, Ya-jun Cao, Yan Pan, Lu Tie, Xue-jun Li   +10 more
doaj   +1 more source

Pharmacokinetic profiling of imatinib in relation to CYP3A4 activity in leukaemia patients

British Journal of Clinical Pharmacology, EarlyView.
Aim Imatinib pharmacokinetics exhibit large interindividual variability because of differences in CYP3A4 activity—the main imatinib‐metabolizing enzyme. While therapeutic drug monitoring is effective, it requires steady‐state conditions and frequent sampling.
Anna Sofie Buhl Rasmussen, Mathilde Rønne Koch, Cecilie Utke Rank, Christen Lykkegaard Andersen, Allan Weimann, Maria Thastrup, Tianwu Yang, Trine Meldgaard Lund, Ib Jarle Christensen, Flemming Nielsen, Tore Bjerregaard Stage, Sara Bisgaard Jensen, Mette Klarskov Andersen, Kjeld Schmiegelow, Kim Dalhoff   +14 more
wiley   +1 more source

A descriptive case series of hepatotoxicity associated with CFTR modulators and possible relevance of pharmacogenetic polymorphisms in cystic fibrosis patients

British Journal of Clinical Pharmacology, EarlyView.
Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are widely used in patients with cystic fibrosis and significantly improve respiratory function and quality of life. However, their effectiveness may be limited by liver damage, which sometimes leads to treatment discontinuation, and the mechanisms underlying this remain poorly ...
Clara Laffitte Redondo, Venceslas Bourdin, Abd El Kader Ait Tayeb, Sihem Benaboud, Inès Martins, Caroline Joyau, Myriam Benhamida, Isabelle Sermet‐Gaudelus, Clémence Martin, Pierre Régis Burgel, Céline Verstuyft, Laurent Chouchana, Estelle Ayme‐Dietrich   +12 more
wiley   +1 more source

Coronary Perforation During Excimer Laser Angioplasty in a Patient With Prior Thoracic Radiotherapy

Catheterization and Cardiovascular Interventions, EarlyView.
ABSTRACT Background Management of heavily calcified coronary lesions remains challenging despite advances in plaque‐modifying technologies. Excimer laser coronary angioplasty (ELCA) is an effective adjunctive strategy with a low risk of no‐reflow. Case Summary A 75‐year‐old woman with non–ST‐segment elevation acute coronary syndrome and severe left ...
Francesco Maria Sparasci, Alessandro Cafaro, Dionigi Fischetti, Alessandro Mandurino‐Mirizzi   +3 more
wiley   +1 more source

Atorvastatin before percutaneous coronary intervention: A systematic review and meta-analysis.

PLoS ONE
Atorvastatin is widely recommended for long-term secondary prevention in STEMI patients with no contraindication. Although high-dose atorvastatin has been shown to reduce important patient outcomes such as MACE, there is still doubt that high-dose ...
Mariano García-Campa, Ramiro Flores-Ramírez, Sabrina Rojo-Garza, Edgar Francisco Carrizales-Sepúlveda, Diego Regalado-Ceballos, Raúl Reyes-Araiza, Neri Álvarez-Villalobos, Rene Rodríguez-Gutiérrez, José Ramón Azpiri-López   +8 more
doaj   +1 more source

Structural Changes of the Pancreas in Female Albino Rats Treated with the Atorvastatin and the Alleviating Effect of Propolis : Histological and Biochemical Study [PDF]

The Egyptian Journal of Histology
Introduction: Atorvastatin is "HMG-COA" reductase inhibitors" that is widely used for management of hyperlipidemia particularly in patients with risk of cardio and cerebrovascular stroke.
Eman sheet, zahraa taboo, waleed kasim
doaj   +1 more source